000			03860nam a2200469 i 4500
999			_c362807 _d362807 _x1
001			362807
003			ES-MaUEC
005			20230102121619.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			210924s2021 sz a s |||| 0|eng d
020			_a9783030586508
024	7		_a10.1007/978-3-030-58650-8 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM145 _b2021 EB
100	1		_aGolightly, Larry K. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9682231
245	1	0	_aRenal Pharmacotherapy . _bDosage Adjustment of Medications Eliminated by the Kidneys _cby Larry K. Golightly, Isaac Teitelbaum, Bonita A. Simendinger, Tyree H. Kiser, Gerard R. Barber, Nancy M. Stolpman
250			_aSecond edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
264		4	_c2021
300			_a1 recurso en línea (XXVI, 827 páginas) _bilustraciones
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
505	0		_aA: Acamprosate to Aztreonam -- B: Bacitracin to Butorphanol -- : Capecitabine to Cycloserine -- D: Dabigatran to Dyphylline -- E: Edetate Calcium Disodium to Exenatide -- F: Famciclovir to Fosfomycin -- H: Hetastarch to Hydroxyurea -- I: Ibandronate to Itraconazole -- K: Kanamycin to Ketorolac -- L: Lacosamide to Lurasidone -- M: Magnesium Citrate to Mycophenolate Mofetil -- N: Nabumetone to Norfloxacin -- O: Ofloxacin to Oxcarbazepine -- P: Paliperidone to Pyridostigmine -- Q: Quinapril to Quinine -- R: Ramipril to Ruxolitinib -- S: Salsalate to Sunitinib -- T: Tadalafil to Trospium -- V: Valacyclovir to Voriconazole -- Z: Zalcitabine to Zonisamide -- Proprietary Name Index.
520			_aTo promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.
988			_aSpringer_Medicine_2021
650		7	_2embne _9675427 _aMedicamentos _xDosificación
700	1		_aTeitelbaum, Isaac _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9682232
700	1		_aSimendinger, Bonita A. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9682233
700	1		_aKiser, Tyree H. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9682234
700	1		_aBarber, Gerard R. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9682235
700	1		_aStolpman, Nancy M. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9682236
776	0	8	_iPrinted edition: _z9783030586492
776	0	8	_iPrinted edition: _z9783030586515
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-58650-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b02/2022 _dz _ek _zSI